<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Hologic Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/hologic-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ISR) IsoRay Begins GliaSite Shipment</title>
		<link>http://www.stockbloghub.com/2011/12/08/isr-isoray-begins-gliasite-shipment/87902</link>
		<comments>http://www.stockbloghub.com/2011/12/08/isr-isoray-begins-gliasite-shipment/87902#comments</comments>
		<pubDate>Thu, 08 Dec 2011 19:02:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hologic Inc]]></category>
		<category><![CDATA[HOLX]]></category>
		<category><![CDATA[IsoRay Inc]]></category>
		<category><![CDATA[ISR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87902</guid>
		<description><![CDATA[Medical isotope maker IsoRay Inc (ISR) said that it has commenced the shipment for its GliaSite radiation therapy system, a balloon catheter used in treating brain cancer. This follows the recent approval of the device by the Washington State Department of Health, which paved the way for its launch in the U.S. GliaSite was approved by the U.S. Food and Drug Administration (“FDA”) in September 2011. The Washington-based company noted that GliaSite has already started attracting the attention of physicians and patients. Brain cancer is among the fastest growing cancers with more than 575 people being diagnosed with this condition in the U.S. every day. Treatment of brain tumors is challenging as these tumors are difficult to remove completely given the risk of damaging the brain. Typically, surgeons remove most ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/08/isr-isoray-begins-gliasite-shipment/87902/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HOLX) Hologic Launches C-View Software</title>
		<link>http://www.stockbloghub.com/2011/11/30/holx-hologic-launches-c-view-software/87723</link>
		<comments>http://www.stockbloghub.com/2011/11/30/holx-hologic-launches-c-view-software/87723#comments</comments>
		<pubDate>Wed, 30 Nov 2011 19:47:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Conceptus Inc]]></category>
		<category><![CDATA[CPTS]]></category>
		<category><![CDATA[Hologic Inc]]></category>
		<category><![CDATA[HOLX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87723</guid>
		<description><![CDATA[Hologic (HOLX), a leading player in the field of women’s health, has released its C-View synthesized 2D image reconstruction algorithm. This eliminates the requirement of a conventional 2D mammogram as a part of a 3D mammography (tomosynthesis breast cancer screening). The C-View software creates a 2D image from a single tomosynthesis, thus doing away with the need for additional 2D exposures. Hologic will feature the new algorithm along with its Selenia Dimensions breast tomosynthesis system at the annual meeting of the Radiological Society of North America (RSNA), currently underway in Chicago. Earlier this year, Hologic received approval from the US Food and Drug Administration (FDA) for its Selenia Dimensions 3D digital mammography tomosynthesis system. The device is capable of producing both 3D and conventional 2D images that can be used ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/30/holx-hologic-launches-c-view-software/87723/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISR) IsoRay&#8217;s GliaSite Gets Final Nod</title>
		<link>http://www.stockbloghub.com/2011/11/28/isr-isorays-gliasite-gets-final-nod/87635</link>
		<comments>http://www.stockbloghub.com/2011/11/28/isr-isorays-gliasite-gets-final-nod/87635#comments</comments>
		<pubDate>Mon, 28 Nov 2011 20:45:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Hologic Inc]]></category>
		<category><![CDATA[HOLX]]></category>
		<category><![CDATA[IsoRay Inc]]></category>
		<category><![CDATA[ISR]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87635</guid>
		<description><![CDATA[IsoRay Inc (ISR), which makes the Cesium-131 internal radiation therapy (brachytherapy) isotope, has crossed the last regulatory hurdle for its GliaSite radiation therapy system, a balloon catheter used in treating brain cancer. The product has been cleared by the Washington State Department of Health, representing the final step required to commence its commercialization in the U.S. GliaSite was approved by the U.S. Food and Drug Administration (“FDA”) in September 2011. IsoRay had acquired the exclusive global distribution rights to GliaSite from Hologic Inc (HOLX) in June 2010. The company, in June 2011, secured the exclusive global licensing rights to Iotrex, a key component in the GliaSite system, from Dr. Reddy’s Laboratories (RDY). Brain cancer is among the fastest growing cancers with more than 575 people being diagnosed with this condition ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/28/isr-isorays-gliasite-gets-final-nod/87635/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HOLX) Hologic Earnings Report Shows Strong Growth</title>
		<link>http://www.stockbloghub.com/2011/05/04/holx-hologic-earnings-report-shows-strong-growth/73177</link>
		<comments>http://www.stockbloghub.com/2011/05/04/holx-hologic-earnings-report-shows-strong-growth/73177#comments</comments>
		<pubDate>Wed, 04 May 2011 16:37:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Conceptus Inc]]></category>
		<category><![CDATA[CPTS]]></category>
		<category><![CDATA[Hologic Inc]]></category>
		<category><![CDATA[HOLX]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73177</guid>
		<description><![CDATA[Hologic (HOLX) reported an adjusted EPS of 30 cents during the second quarter of fiscal 2011, surpassing the Zacks Consensus Estimate by 2 cents and a penny above the year-ago quarter. Revenues were $438.7 million, an increase of 4.9% compared to the prior-year quarter and higher than the Zacks Consensus Estimate of $433 million. Hologic operates through four segments ? Breast Health, Diagnostics, GYN (Gynecology) Surgical and Skeletal Health ? which contributed 47%, 32%, 16% and 5%, respectively to the total revenue during the quarter. Barring Diagnostics revenue, which declined 1.2% to $138.2 million during the quarter, the other three segments recorded a robust growth of 8.7% ($205.9 million), 6.5% ($71.5 million) and 7.1% ($23.1 million), respectively. The strong growth witnessed by Breast Health was primarily driven by the rise ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/04/holx-hologic-earnings-report-shows-strong-growth/73177/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AA) Company News for May 03, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/05/03/aa-company-news-for-may-03-2011-corporate-summary/73019</link>
		<comments>http://www.stockbloghub.com/2011/05/03/aa-company-news-for-may-03-2011-corporate-summary/73019#comments</comments>
		<pubDate>Tue, 03 May 2011 17:53:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Aluminum]]></category>
		<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[AA]]></category>
		<category><![CDATA[ACI]]></category>
		<category><![CDATA[Alcoa Inc.]]></category>
		<category><![CDATA[Arch Coal Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Community Health Systems Inc.]]></category>
		<category><![CDATA[CYH]]></category>
		<category><![CDATA[DISH]]></category>
		<category><![CDATA[Dish Network Corporation]]></category>
		<category><![CDATA[EchoStar Corporation]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Hologic Inc]]></category>
		<category><![CDATA[HOLX]]></category>
		<category><![CDATA[ICO]]></category>
		<category><![CDATA[International Coal Group Inc]]></category>
		<category><![CDATA[PFG]]></category>
		<category><![CDATA[Principal Financial Group Inc]]></category>
		<category><![CDATA[SATS]]></category>
		<category><![CDATA[SNE]]></category>
		<category><![CDATA[Sony Corporation]]></category>
		<category><![CDATA[Tenet Healthcare Corporation]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[THC]]></category>
		<category><![CDATA[TIVO]]></category>
		<category><![CDATA[TiVo Inc.]]></category>
		<category><![CDATA[VLCM]]></category>
		<category><![CDATA[Volcom Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73019</guid>
		<description><![CDATA[•    Arch Coal, Inc. (NYSE:ACI) and International Coal Group, Inc. (NYSE:ICO) announced that they have signed a definitive agreement under which Arch will acquire all of the outstanding shares of ICG for $14.60 per share in an all-cash transaction valued at $3.4 billion •    Teva Pharmaceutical (NASDAQ:TEVA) and Cephalon (NASDAQ:CEPH) said that their respective boards of directors unanimously approved a definitive agreement under which Teva will acquire Cephalon and all of its outstanding shares for $81.50 per share in cash, with a total enterprise value of about $6.8 billion •    Principal Financial Group (NYSE:PFG) reported Q1 EPS of $0.71, marginally higher than the Zacks Consensus Estimate of $0.70 per share. Revenues for the quarter rose 4% year-over-year to $2.05 billion, just short of the Zacks Consensus Estimate of $2.055 billion ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/aa-company-news-for-may-03-2011-corporate-summary/73019/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HOLX) Hologic&#8217;s Report Surpasses Wall Street&#8217;s Estimate</title>
		<link>http://www.stockbloghub.com/2010/02/02/holx-hologics-report-surpasses-wall-streets-estimate/26704</link>
		<comments>http://www.stockbloghub.com/2010/02/02/holx-hologics-report-surpasses-wall-streets-estimate/26704#comments</comments>
		<pubDate>Wed, 03 Feb 2010 01:32:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Hologic Inc]]></category>
		<category><![CDATA[HOLX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26704</guid>
		<description><![CDATA[Hologic Inc.’s (HOLX) first quarter fiscal 2010 (ended Dec 26, 2009) earnings of 29 cents per share (excluding special items) were above the Zacks Consensus Estimate of 26 cents. The company had earned 31 cents in the year-ago quarter (ended Dec 27, 2008). Hologic reported net income of $74.6 million (excluding special items), compared to a net income of $80.7 million a year earlier. Estimate Revisions Trend Only one out of the seventeen analysts following the stock lowered earnings estimates for fiscal 2010. Similarly one analyst raised earnings estimates over the last 7 days. Over the last 30 days, only two of the seventeen analysts covering the stock increased estimates for full year 2010 while one of the analysts lowered earnings estimates. This implies that a majority of the analysts ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/02/holx-hologics-report-surpasses-wall-streets-estimate/26704/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HOLX) Analysts Upgrade Hologic Pre-Earnings</title>
		<link>http://www.stockbloghub.com/2010/02/01/holx-analysts-upgrade-hologic-pre-earnings/26633</link>
		<comments>http://www.stockbloghub.com/2010/02/01/holx-analysts-upgrade-hologic-pre-earnings/26633#comments</comments>
		<pubDate>Mon, 01 Feb 2010 23:24:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Hologic Inc]]></category>
		<category><![CDATA[HOLX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26633</guid>
		<description><![CDATA[Recently, we upgraded Hologic, Inc. (HOLX) to Neutral from Underperform with a price target of $16.00. Even though we are concerned about the strong competition and declining revenues which are largely attributable to the tough economic and capital spending environment, the company’s broad product portfolio pleases us. The growth-by-acquisition strategy adopted by the company has significantly expanded its product portfolio. Hologic is on the lookout for more such opportunities, which should contribute to growth. In 2009, the U.S. Food and Drug Administration (FDA) approved a more flexible design of Hologic’s MammoSite system, which provides radiation seeds to prevent recurrences of breast cancer. The MammoSite ML (multi-lumen) radiation therapy system allows physicians to target radiation at areas which are most likely to be affected by cancer and shift the dose away ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/01/holx-analysts-upgrade-hologic-pre-earnings/26633/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(UNH) Healthcare Stock Review &#8211; December 2009 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/12/17/unh-healthcare-stock-review-dec-2009-industry-outlook/23150</link>
		<comments>http://www.stockbloghub.com/2009/12/17/unh-healthcare-stock-review-dec-2009-industry-outlook/23150#comments</comments>
		<pubDate>Fri, 18 Dec 2009 00:58:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Health Care Plans]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BIOS]]></category>
		<category><![CDATA[BioScrip Inc.]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CI]]></category>
		<category><![CDATA[CIGNA Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Hologic Inc]]></category>
		<category><![CDATA[HOLX]]></category>
		<category><![CDATA[HUM]]></category>
		<category><![CDATA[Humana Inc.]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[LMNX]]></category>
		<category><![CDATA[Luminex Corporation]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MOH]]></category>
		<category><![CDATA[Molina Healthcare Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Polypore International Inc]]></category>
		<category><![CDATA[PPO]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Unitedhealth Group]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23150</guid>
		<description><![CDATA[OVERVIEW The healthcare sector comprises different industries, ranging from managed care organizations, healthcare facilities providers and medical devices manufacturers to biotech and pharmaceutical companies. Consequently, we believe that investors in this sector should be mindful of the different drivers and appropriate metrics associated with the various sub-sectors. In the present scenario, investor sentiment in healthcare continues to be driven by decisions in Congress related to government funding and the state of the broader economy. In view of the ongoing healthcare reform debate in Congress, healthcare policy changes remain an important indicator to investing in the sector. Even though legislation &#8212; which aims to cover nearly all Americans by providing government subsidies to help pay premiums irrespective of health or income &#8212; was passed in the House of Representatives, it is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/17/unh-healthcare-stock-review-dec-2009-industry-outlook/23150/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HOLX) Hologic, Incorporated &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2009/11/17/holx-hologic-incorporated-bear-of-the-day/20744</link>
		<comments>http://www.stockbloghub.com/2009/11/17/holx-hologic-incorporated-bear-of-the-day/20744#comments</comments>
		<pubDate>Tue, 17 Nov 2009 14:57:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Hologic Inc]]></category>
		<category><![CDATA[HOLX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20744</guid>
		<description><![CDATA[Hologic, Inc. (HOLX) reported fourth quarter earnings of 28 cents per share, above the Zacks Consensus Estimate of 26 cents, but a couple of cents below the year-ago earnings. For fiscal 2009, the company earned $1.17 per share, a cent below the year-ago earnings. Revenues declined 8.9% in the reported quarter and 2% in fiscal 2009. We remain concerned about the decline, which is largely attributable to the stringent economic and capital spending environment. Furthermore, Hologic&#8217;s strategy to grow by acquisitions has inherent risks. Strong competition confronting the company&#8217;s products also concerns us. Consequently, we downgrade the stock to Underperform with a price target of $14. Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/17/holx-hologic-incorporated-bear-of-the-day/20744/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HOLX) Hologic Beats Consensus Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2009/11/12/holx-hologic-beats-consensus-earnings-estimates/20373</link>
		<comments>http://www.stockbloghub.com/2009/11/12/holx-hologic-beats-consensus-earnings-estimates/20373#comments</comments>
		<pubDate>Thu, 12 Nov 2009 16:28:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Hologic Inc]]></category>
		<category><![CDATA[HOLX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20373</guid>
		<description><![CDATA[Hologic, Inc. (HOLX) reported fourth-quarter earnings of 28 cents per share, which beat the Zacks Consensus Estimate of 26 cents. The company earned 30 cents in the year-ago quarter. For full fiscal 2009, the company earned $1.17 per share, which was above the Zacks Consensus Estimate by 2 cents but below the year-ago earnings by a cent. Quarterly results Revenues for the quarter were $402.8 million, in contrast to $442.5 million in the year-ago quarter thus representing a 8.9% decline. The decrease was primarily driven by the year-over-year decline in sales of Selenia systems, attributable primarily to the current economic environment, which resulted in delays and reductions in hospital capital spending and longer sales cycles. This overall decline was partially offset by growth in Diagnostics and Surgical product sales Incorporatedrease ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/12/holx-hologic-beats-consensus-earnings-estimates/20373/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HOLX) Hologic Breast Cancer Product Gets FDA Nod</title>
		<link>http://www.stockbloghub.com/2009/09/02/holx-hologic-product-gets-fda-nod/14272</link>
		<comments>http://www.stockbloghub.com/2009/09/02/holx-hologic-product-gets-fda-nod/14272#comments</comments>
		<pubDate>Thu, 03 Sep 2009 01:44:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Hologic Inc]]></category>
		<category><![CDATA[HOLX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14272</guid>
		<description><![CDATA[Yesterday, the U.S. Food and Drug Administration (FDA) approved a more flexible design of Hologic Inc.’s (HOLX) MammoSite system, which provides radiation seeds to prevent recurrences of breast cancer. The company intends to launch the radiation therapy system, designed to treat early-stage breast cancer, in the first quarter of fiscal 2010. The MammoSite ML (multi-lumen) radiation therapy system allows physicians to target radiation to areas which are most likely to be affected by cancer and shift the dose away from areas that do not need it. MammoSite devices include balloon catheters that are inserted into the body after the removal of a tumor. A pellet of radioactive material is inside the catheter. The radiation treatment is completed in just five days. The therapy aims to prevent recurrence without affecting healthy ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/02/holx-hologic-product-gets-fda-nod/14272/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

